source
- Genmab’s Rina-S ADC cuts risk of progression and death in Phase 3 ovarian cancer trialGenmab reported results from its Phase 3 RAINFOL-02 trial of the FRα‑directed antibody‑drug conjugate Rina‑S (rinatabart sesutecan) in patients with platinum‑resistant ovarian cancer. In the inten…
- GSK gains another cancer drug approval and unveils promising chemo data as it prepares for lung cancer approvalGSK received regulatory approval this week for one of its cancer medicines in an additional tumor indication, expanding the portfolio that has grown since the company re-entered oncology a decade a…